Wellnex Life’s (ASX: WNX) joint venture partner OneLife Botanicals has successfully launched the new medicinal cannabis brand – Wellness Life.
Wellness Life has commenced sales with product being prescribed by registered medical professionals in Australia and dispensed by pharmacies.
Wellness Life provides patients high quality Australian medicinal cannabis products, with distribution of Wellness Life being facilitated by one of Australia largest medicinal cannabis distributors to pharmacies in in the Entourage Effect.
Industry experts Dr Mihindu Jayasuriya and Dr Tony Farag have been appointed as senior medical advisors for Wellness Life to complement the previous appointment of Dr Sylvia Victor (as the lead on the JV) to both provide training, education and to prescribe Wellness Life products to patients.
Dr Jayasuriya and Dr Farag have commenced training to select pharmacies on the medicinal cannabis market and more specifically on Wellness Life. This will accelerate the knowledge on Wellness Life in both pharmacies and more importantly with registered practitioners which will increase the brand awareness in the medical community.
About SAS Market
The Special Access Scheme (SAS) allows registered medical practitioners to prescribe medicinal cannabis products to patients not included on the Australian Register of Therapeutic Goods (ATRG) that can only be dispensed in a pharmacy.
The medicinal cannabis market in Australia is projected to reach USD 356.7 million in 2024, with a compound growth rate (CAGR) of 4.58% from 2024 to 2029, potentially reaching USD 446.3 million by 2029.
“The launch of Wellness Life is an exciting development, and we are well positioned to take advantage of the growing demand for prescription medicinal cannabis. We have quality Australian product manufactured by OneLife Botanicals, an experienced team led by Dr Sylvia Victor and great partners which makes this project very exciting,” Wellnex Life CEO, George Karafotias, said.
